Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.
J Cardiothorac Vasc Anesth. 2022 Feb;36(2):529-533. doi: 10.1053/j.jvca.2021.04.037. Epub 2021 May 3.
Current evidence supports centralization of patients with refractory acute respiratory distress syndrome (ARDS) to institutions with a high level of expertise and with extracorporeal membrane oxygenation (ECMO) capabilities. The aim of this study was to analyze and report the data of transferred refractory ARDS patients managed with venovenous (VV) ECMO at a national referral center over the last 11 years.
Observational study.
Referral center in Italy.
The study comprised 100 patients treated from May 2009-November 2020.
None.
The mean age was 54 ± 14 years, and 65% of patients were male. Patients were treated throughout the year, with seasonal peaks in the winter months. The majority of patients were referred from hospitals within the Lombardia region (81%), mainly from the city of Milan and surrounding area (36% of the total). The most common etiology of refractory ARDS was H1N1 influenza A (42 patients [42%]), followed by bacterial pneumonia (35 patients [35%]), and severe acute respiratory syndrome due to Sars-CoV-2 infection (five patients [5%]). All patients were severely hypoxic at the time of VV ECMO treatment. No transport-related complication was recorded. The most common configuration used in the authors' clinical practice was a bicaval dual-lumen configuration (61 patients [61%]), followed by a femoro-jugular configuration (38 patients [38%]). The intensive care unit survival rate was 55%.
Referral to a specialized center for VV ECMO treatment should be considered expeditiously in case of refractory ARDS, which often is lethal. Transport of patients with an unstable condition, although challenging, is feasible, and centralization of patient care is associated with good outcomes.
目前的证据支持将难治性急性呼吸窘迫综合征(ARDS)患者集中到具有高水平专业知识和体外膜氧合(ECMO)能力的机构。本研究旨在分析和报告过去 11 年来在国家转诊中心接受静脉-静脉(VV)ECMO 治疗的难治性 ARDS 患者的数据。
观察性研究。
意大利转诊中心。
该研究纳入了 2009 年 5 月至 2020 年 11 月期间接受治疗的 100 名患者。
无。
患者的平均年龄为 54±14 岁,65%为男性。患者全年接受治疗,冬季月份有季节性高峰。大多数患者来自伦巴第大区的医院(81%),主要来自米兰市及其周边地区(占总数的 36%)。难治性 ARDS 的最常见病因是甲型 H1N1 流感(42 例[42%]),其次是细菌性肺炎(35 例[35%])和严重急性呼吸综合征冠状病毒 2 感染(5 例[5%])。所有患者在接受 VV ECMO 治疗时均严重缺氧。未记录到与转运相关的并发症。作者的临床实践中最常用的配置是双腔颈内静脉配置(61 例[61%]),其次是股-颈配置(38 例[38%])。重症监护病房的生存率为 55%。
对于难治性 ARDS 患者,应迅速考虑转诊至专门的 VV ECMO 治疗中心,因为该病通常是致命的。转运病情不稳定的患者虽然具有挑战性,但可行,集中患者治疗与良好的结局相关。